SCHEMBL6404356

SCHEMBL6404356

O=P(O)(O)Oc1cccc(O)c1CCCCc1cccc(O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.44
HDAC6 Q9UBN7 1/20 0.43
INPPL1 O15357 1/20 0.41
INPP5B P32019 1/20 0.41
INPP5A Q14642 1/20 0.41
F2 P00734 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
POLB P06746 1/20 0.39
TYR P14679 1/20 0.39
GAA P10253 1/20 0.38
CALM1 P0DP23 1/20 0.37
HTR2B P41595 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395816 0.97 MGLL (0.41) MGLLHDAC6INPPL1INPP5BINPP5A
SCHEMBL6396526 0.92 F2 (0.45) MGLLINPPL1INPP5BINPP5AF2
SCHEMBL6401472 0.90 MGLL (0.44) MGLLHDAC6INPPL1INPP5BINPP5A
SCHEMBL6398398 0.87 SLC28A3 (0.44) MGLLHDAC6INPPL1INPP5BINPP5A
SCHEMBL6396051 0.86 ACHE (0.46) MGLLINPPL1INPP5BINPP5ACALM1
SCHEMBL6396309 0.84 SLC28A3 (0.46) INPPL1INPP5BINPP5AGAACALM1
SCHEMBL6397718 0.81 F2 (0.45) INPPL1INPP5BINPP5AF2DRD2
SCHEMBL6403447 0.80 MGLL (0.38) MGLLHDAC6INPPL1INPP5BINPP5A
SCHEMBL6395137 0.80 ACHE (0.47) MGLLHDAC6F2TYRGAA
SCHEMBL6397196 0.80 MGLL (0.45) MGLLHDAC6INPPL1INPP5BINPP5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885HDAC6 4653/4885INPPL1 82/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MGLL 3439/4885HDAC6 4532/4885INPPL1 85/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MGLL 3457/4885HDAC6 4653/4885INPPL1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.